» Articles » PMID: 6289994

Muscarinic Receptors on Dopamine Terminals in the Cat Caudate Nucleus: Neuromodulation of [3H]dopamine Release in Vitro by Endogenous Acetylcholine

Overview
Journal Brain Res
Specialty Neurology
Date 1982 Sep 23
PMID 6289994
Citations 21
Authors
Affiliations
Soon will be listed here.
Abstract

The directly acting muscarinic receptor agonist oxotremorine (1.8-10 microM) produced an increase in electrically evoked [3H] dopamine release from slices of the cat caudate. The maximal increase caused by oxotremorine was 40%, and was antagonized by the muscarinic receptor blocking agent atropine (0.1 microM). Exposure to the acetylcholinesterase (AChe) inhibitor physostigmine (1 microM) resulted in a 50% increase in electrically evoked [3H]dopamine release. The increase caused by physostigmine was also antagonized by atropine (0.1 microM). Atropine did not, however, alter the modulations in [3H]dopamine release mediated by the dopamine autoreceptor: the increase in electrically evoked [3H]dopamine release caused by the dopamine receptor antagonist S-sulpiride (0.1 microM) and the decrease caused by the dopamine receptor agonist pergolide (30 nM) were unaffected by atropine (0.1 microM). These results indicate that the muscarinic receptor-mediated and dopamine autoreceptor-mediated presynaptic effects on [3H]dopamine release are independent. The present results suggest that in the electrically depolarized caudate slice in vitro, released endogenous acetylcholine may interact with muscarinic receptors facilitating depolarization-evoked [3H]dopamine release, if AChE is inhibited. These muscarinic receptors may be located on dopamine nerve terminals. In the context of present neuroanatomical knowledge, the action of released endogenous acetylcholine on dopamine terminals may be a non-synaptic neuromodulation.

Citing Articles

Omega 3 fatty acid improves sexual and erectile function in BPF-treated rats by upregulating NO/cGMP signaling and steroidogenic enzymes activities.

Odetayo A, Olayaki L Sci Rep. 2023; 13(1):18060.

PMID: 37872365 PMC: 10593954. DOI: 10.1038/s41598-023-45344-4.


Striatal dopamine neurotransmission: regulation of release and uptake.

Sulzer D, Cragg S, Rice M Basal Ganglia. 2016; 6(3):123-148.

PMID: 27141430 PMC: 4850498. DOI: 10.1016/j.baga.2016.02.001.


Muscarinic regulation of dopamine and glutamate transmission in the nucleus accumbens.

Shin J, Adrover M, Wess J, Alvarez V Proc Natl Acad Sci U S A. 2015; 112(26):8124-9.

PMID: 26080439 PMC: 4491757. DOI: 10.1073/pnas.1508846112.


Striatal cholinergic dysfunction as a unifying theme in the pathophysiology of dystonia.

Eskow Jaunarajs K, Bonsi P, Chesselet M, Standaert D, Pisani A Prog Neurobiol. 2015; 127-128:91-107.

PMID: 25697043 PMC: 4420693. DOI: 10.1016/j.pneurobio.2015.02.002.


Striatal cholinergic interneuron regulation and circuit effects.

Lim S, Kang U, McGehee D Front Synaptic Neurosci. 2014; 6:22.

PMID: 25374536 PMC: 4204445. DOI: 10.3389/fnsyn.2014.00022.